{
    "Clinical Trial ID": "NCT00191269",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Dose Level 1",
        "  Gemcitabine at 1000 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.",
        "INTERVENTION 2: ",
        "  Dose Level 2",
        "  Gemcitabine at 1250 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically and/or cytologically confirmed breast cancer",
        "  Received prior chemotherapy for metastatic breast cancer with anthracycline and taxane regimen",
        "  To have at least one measurable region",
        "  PS: 0-1",
        "  To have adequate organ function (bone marrow, liver and renal function)",
        "Exclusion Criteria:",
        "  To have Interstitial pneumonia or pulmonary fibrosis",
        "  To have inflammatory carcinoma",
        "  Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery",
        "  To have brain metastasis with symptom",
        "  To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Tumor Response",
        "  Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatment.",
        "  Time frame: baseline to measured progressive disease",
        "Results 1: ",
        "  Arm/Group Title: Dose Level 1",
        "  Arm/Group Description: Gemcitabine at 1000 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 0",
        "  Partial Response: 0",
        "  Long Stable Disease: 1",
        "  Stable Disease: 1",
        "  Progressive Disease: 2",
        "Not Evaluable: 2",
        "Results 2: ",
        "  Arm/Group Title: Dose Level 2",
        "  Arm/Group Description: Gemcitabine at 1250 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.",
        "  Overall Number of Participants Analyzed: 62",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response: 1",
        "  Partial Response: 4",
        "  Long Stable Disease: 4",
        "  Stable Disease: 16",
        "  Progressive Disease: 32",
        "Not Evaluable: 5"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1",
        "  Cardiac failure acute 0/6 (0.00%)",
        "  Cataract 0/6 (0.00%)",
        "  Cellulitis 1/6 (16.67%)",
        "  Infection 0/6 (0.00%)",
        "  Blood lactate dehydrogenase increased 0/6 (0.00%)",
        "  Anorexia 0/6 (0.00%)",
        "  Femur fracture 0/6 (0.00%)",
        "  Brain oedema 0/6 (0.00%)",
        "  Dyspnoea 1/6 (16.67%)",
        "  Acute respiratory failure 0/6 (0.00%)",
        "  Catheterisation venous 0/6 (0.00%)",
        "  Raynaud's phenomenon 0/6 (0.00%)",
        "Adverse Events 2:",
        "  Total: 10",
        "  Cardiac failure acute 1/62 (1.61%)",
        "  Cataract 1/62 (1.61%)",
        "  Cellulitis 1/62 (1.61%)",
        "  Infection 1/62 (1.61%)",
        "  Blood lactate dehydrogenase increased 1/62 (1.61%)",
        "  Anorexia 1/62 (1.61%)",
        "  Femur fracture 1/62 (1.61%)",
        "  Brain oedema 1/62 (1.61%)",
        "  Dyspnoea 0/62 (0.00%)",
        "  Acute respiratory failure 1/62 (1.61%)",
        "  Catheterisation venous 2/62 (3.23%)"
    ]
}